Labtech International, a distributor of life science instrumentation in the UK and France, has agreed to provide a global sales and marketing support service for the G-Storm PCR machines that target the international life science research market.
The agreement allows Agilegene Technologies, the UK manufacturer of the G-Storm PCR machines, to focus solely on engineering and software development of future products.
With 19 years of sales and marketing experience in the life science instrumentation sector, Labtech International, based in Ringmer, Sussex, is suitably equipped to offer G-Storm's global distributors and customers a high-quality sales support service.
The G-Storm thermal cyclers in a striking new black livery are purpose-built to meet the demands of molecular biology. The G-Storm touch-screen user interface is easy to use and makes programming, file management and cycler control a simple process.
Labtech to support G-Storm PCR machines
G-Storm machines are given a new black livery
You may also like
Trending Articles
You may also like
Manufacturing
Beyond the Vacuum Pump: Is your Vacuum System costing more than you think?
Many facilities continue to rely on oil-lubricated vacuum pumps that were installed years ago. The question is no longer whether these pumps work. The question is whether they remain the most efficient solution for today's operational, environmental and productivity requirements
Manufacturing
Stevanato Group and Aptar Pharma collaborate to accelerate prefilled syringe system selection
Joint system-level testing combines Stevanato's glass syringes with Aptar's elastomer components to provide key data earlier in development and inform packaging decisions for sensitive biologics and other injectable therapies
Manufacturing
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk